Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy associated with psoriasis, in which the recognition of different cytokines has changed the therapeutic approach.

Different studies have shown the efficacy and safety of anti-tumor necrosis factor (TNF)-α in PsA, but discontinuation or switching is quite common.

Data indicate that the main reason for switching to a second anti-TNFα agent is represented by lack of effect, followed by inefficacy and, more rarely, adverse events.